High-rolling investors have positioned themselves bullish on CRISPR Therapeutics CRSP, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in CRSP often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 10 options trades for CRISPR Therapeutics. This is not a typical pattern.
The sentiment among these major traders is split, with 80% bullish and 20% bearish. Among all the options we identified, there was one put, amounting to $28,000, and 9 calls, totaling $492,132.
What's The Price Target?
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $25.0 and $50.0 for CRISPR Therapeutics, spanning the last three months.
Volume & Open Interest Development
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for CRISPR Therapeutics's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of CRISPR Therapeutics's whale activity within a strike price range from $25.0 to $50.0 in the last 30 days.
CRISPR Therapeutics Option Volume And Open Interest Over Last 30 Days
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CRSP | CALL | TRADE | BULLISH | 01/17/25 | $9.5 | $9.1 | $9.5 | $32.50 | $104.5K | 253 | 110 |
| CRSP | CALL | SWEEP | BULLISH | 01/16/26 | $9.7 | $9.4 | $9.7 | $45.00 | $78.5K | 971 | 81 |
| CRSP | CALL | TRADE | BEARISH | 01/15/27 | $25.2 | $24.1 | $24.46 | $25.00 | $61.1K | 95 | 25 |
| CRSP | CALL | SWEEP | BEARISH | 01/16/26 | $20.8 | $18.2 | $18.5 | $30.00 | $59.3K | 167 | 57 |
| CRSP | CALL | TRADE | BULLISH | 01/15/27 | $20.8 | $20.0 | $20.5 | $30.00 | $51.2K | 46 | 27 |
About CRISPR Therapeutics
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
In light of the recent options history for CRISPR Therapeutics, it's now appropriate to focus on the company itself. We aim to explore its current performance.
CRISPR Therapeutics's Current Market Status
- Trading volume stands at 1,496,524, with CRSP's price up by 0.73%, positioned at $41.32.
- RSI indicators show the stock to be is currently neutral between overbought and oversold.
- Earnings announcement expected in 44 days.
Expert Opinions on CRISPR Therapeutics
2 market experts have recently issued ratings for this stock, with a consensus target price of $90.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * An analyst from JMP Securities downgraded its action to Market Outperform with a price target of $86. * Consistent in their evaluation, an analyst from Chardan Capital keeps a Buy rating on CRISPR Therapeutics with a target price of $94.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for CRISPR Therapeutics, Benzinga Pro gives you real-time options trades alerts.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
